[HTML][HTML] Efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in EGFR-mutated advanced non-small cell lung cancer (E100VG250): an open-label …
S Zhao, Z Zhang, W Fang, Y Zhang, Z Zhang… - Frontiers in …, 2020 - frontiersin.org
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label …
S Zhao, Z Zhang, W Fang, Y Zhang… - Frontiers in Oncology …, 2020 - jglobal.jst.go.jp
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated
Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase …
Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase …
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label …
S Zhao, Z Zhang, W Fang, Y Zhang… - Frontiers in …, 2020 - pubmed.ncbi.nlm.nih.gov
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label …
S Zhao, Z Zhang, W Fang, Y Zhang, S Hong… - Frontiers in …, 2020 - europepmc.org
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
[HTML][HTML] Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label …
S Zhao, Z Zhang, W Fang, Y Zhang, Z Zhang… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …